Kelleher Financial Advisors Buys New Stake in AstraZeneca PLC $AZN

Kelleher Financial Advisors bought a new stake in shares of AstraZeneca PLC (NASDAQ:AZN) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,015 shares of the company’s stock, valued at approximately $211,000.

Several other large investors also recently added to or reduced their stakes in the stock. NewSquare Capital LLC lifted its position in AstraZeneca by 149.3% in the second quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock worth $25,000 after buying an additional 218 shares during the last quarter. Larson Financial Group LLC grew its holdings in AstraZeneca by 297.9% during the 1st quarter. Larson Financial Group LLC now owns 386 shares of the company’s stock valued at $28,000 after purchasing an additional 289 shares during the last quarter. Richardson Financial Services Inc. boosted its position in shares of AstraZeneca by 59.8% during the second quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock valued at $28,000 after buying an additional 149 shares during the period. Costello Asset Management INC bought a new position in shares of AstraZeneca during the first quarter valued at approximately $29,000. Finally, Maseco LLP bought a new stake in shares of AstraZeneca during the 2nd quarter worth approximately $34,000. 20.35% of the stock is owned by institutional investors.

AstraZeneca Price Performance

Shares of NASDAQ AZN opened at $89.09 on Wednesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67. The stock has a market capitalization of $276.30 billion, a price-to-earnings ratio of 33.49, a PEG ratio of 1.52 and a beta of 0.34. The firm’s 50 day simple moving average is $81.73 and its 200-day simple moving average is $75.87. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $89.32.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Thursday, November 6th. The company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.05. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The firm had revenue of $15.19 billion for the quarter, compared to the consensus estimate of $14.75 billion. During the same period in the prior year, the firm posted $2.08 earnings per share. The firm’s quarterly revenue was up 12.0% compared to the same quarter last year. Analysts expect that AstraZeneca PLC will post 4.51 EPS for the current year.

Wall Street Analysts Forecast Growth

AZN has been the topic of a number of recent research reports. Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, October 8th. Jefferies Financial Group started coverage on AstraZeneca in a research note on Monday, October 27th. They issued a “buy” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of AstraZeneca from a “hold” rating to a “sell” rating in a research report on Thursday, October 16th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $86.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.